The MLL-AF9 oncogene -one of the most frequent MLL/HRX/ALL-1 rearrangements found in infantile and therapy-related leukaemias -originates from t(9;11) (p22;q23) and is mainly associated with monocytic acute myeloid leukaemia (AML-M5; FAB-classification). Here, we investigated the MLL-AF9 function by means of an antisense phosphorothioate-oligodeoxyribonucleotide (MLL-AF9-PS-ODNas) using the THP-1 AML-M5 cell line carrying t(9;11). Having confirmed that MLL-AF9-PS-ODNas induces strong inhibition of THP-1 cell growth, but only a moderate increase in apoptosis, we found that MLL-AF9-PS-ODNas did not induce morphofunctional terminal differentiation or restore M-CSF-, G-CSF-or GM-CSF-induced differentiation. Moreover, THP-1 cells showed the same phenotype with/without MLL-AF9-PS-ODNas. In THP-1 cells differentiated to mature macrophage-like cells by PMA/TPA or ATRA, MLL-AF9 expression was downregulated. Thus, in the monocytic lineage, MLL-AF9 may be expressed only in early phases and can induce deregulated amplification in both nonmalignant and malignant cells, maintaining the monocytic phenotype without blocking final maturation. Our findings suggest that: (1) as well as directly promoting cell growth, MLL-AF9 may also indirectly determine phenotype; (2) other leukaemogenic mutations associated with MLL-AF9-related leukaemias should be searched for mainly in processes of resistance to apoptosis (where MLL-AF9 may play only a limited role) and differentiation blockage (where MLL-AF9 may play no role).
Results and discussion
Most infantile leukaemias harbour MLL/ALL-1/HRX gene rearrangements (on 11q23), which are also frequently found in therapy-related leukaemias (Biondi et al., 2000) . The MLL-AF9 fusion gene originates from the translocation t(9;11)(p22;q23) (Iida et al., 1993) , which is mainly associated with monocytic acute myeloid leukaemia (AML-M5; French-American-British classification) (Swansbury et al., 1998) . In mice, the expression of an MLL fusion protein is necessary, but not sufficient for leukaemogenesis (Ayton and Cleary, 2001) . Introducing MLL-AF9 into normal and transformed mouse/avian models led to an initial, nonmalignant expansion of myeloid precursors both in vivo and in vitro (Corral et al., 1996; Dobson et al., 1999; Johnson et al., 2003; Schulte et al., 2002) , indicating that the MLL-AF9 oncogene disrupts the normal proliferation and/or survival of myeloid progenitors. The MLL-AF9, MLL-ENL and MLL-ELL fusion proteins abrogate GADD34-induced apoptosis (Adler et al., 1999) . Conditional MLL-AF9 expression in U937 pro-monocytic cells induces macrophage differentiation and ultimately cell death (Caslini et al., 2000) , while in 32D myelomonocytic cells it blocks G-CSF-induced granulocytic differentiation (Joh et al., 1999 ). An alternative way of investigating MLL-AF9 function is to use a knockout strategy in cells that spontaneously express this oncogene. To date, only one study has used this approach (Kawagoe et al., 2001) . Using an antisense phosphorothioate-oligodeoxyribonucleotide complementary to the MLL-AF9 junction coding sequence (MLL-AF9-PS-ODNas), the authors found that MLL-AF9-targeted downregulation reduces HOXA7 and HOXA10 expression and induces apoptosis in the pro-monocytic THP-1 cell line, carrying t(9;11)(p22;q23) and expressing MLL-AF9, which was established from the peripheral blood of a 1-year-old boy with AML-M5 (Tsuchiya et al., 1980; Odero et al., 2000) . In the present study, we further investigated the leukaemogenic role of MLL-AF9 by means of MLL-AF9-PS-ODNas treatment in THP-1 cells, which are resistant to M-(monocyte)-, G-(granulocyte)-and GM-(granulocyte/monocyte)-CSF-(colony-stimulating-factor)-induced differentiation (Brach et al., 1990) .
Using streptolysin-assisted delivery, we first evaluated the effects of MLL-AF9-PS-ODNas on THP-1 under normal culture conditions. In the first 48 h after MLL-AF9-PS-ODNas treatment, there was a strong reduction in THP-1 cell growth with respect to both untreated and MLL-AF9-PS-ODNs-(sense)-treated THP-1 cells (Figure 1a) . The absence of any proliferative effect on HL-60 cells, lacking the t(9;11), treated with either MLL-AF9-PS-ODNas or MLL-AF9-PSODNs (Figure 1b) indicated that the inhibitory effect of MLL-AF9-PS-ODNas is specific to cells expressing MLL-AF9.
Real-time RT-PCR analysis revealed that the 168-bp PCR product of MLL-AF9 mRNA was much lower (o10%) 24 h after treatment with MLL-AF9-PS-ODNas than in untreated cells (Figure 1c ). However, in contrast to the maintained effects observed by Kawagoe et al. (2001) 0 ) were synthesized complementary to the MLL-AF9 junction coding sequence (GenBank-Accession-Number:AJ000161). THP-1 and HL-60 cells were both grown as described previously (Kawagoe et al., 2001) . Streptolysin-O (SLO; Sigma-Chemical-Company, St Louis, MO, USA) was used to permeabilize cells reversibly towards phosphorothioate-oligodeoxyribonucleotides, as previously described (Giles et al., 1998) . Cells (5 Â 10 5 cells/ml) were untreated (n) or treated with 20 mM MLL-AF9-PS-ODNas (J) or 20mM MLL-AF9-PS-ODNs ('). The starting cell number was set at 3 Â 10 5 cells/ml. Cell viability was evaluated by trypan-blue exclusion staining. Values represent the means7s.d. of three separate experiments, (c) Time course of MLL-AF9 mRNA expression in MLL-AF9-PS-ODNas-treated THP-1 cells. The mRNA quantification was achieved by real-time reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated using the 'Rneasy-Mini-Kit' (Qiagen, Santa Clarita, CA, USA), according to the manufacturer's instructions. RT for a total volume of 20 ml was performed using a 'SuperScriptt-First-Strand-Synthesis-Kit' (Gibco-BRL, Basel, Switzerland) according to the manufacturer's instructions. The primers used for PCR were as follows: (1) 
0 with a 168 bp fragment; (2) b2-microglobulin (b2M, used as internal control) forward-5 0 -CTCGCGCTA-CTCTCTCTTTCT-3 0 , reverse-5 0 -TCCATTCTTCAGTAAGTCA-ACT-3 0 with a 162 bp fragment. The primer concentrations were optimized by analysis of their dissociation curves. PCR was performed in a total volume of 20 ml containing 10 ml of 2X SYBRgreen MasterMix (Applied Biosystems, Foster City, CA, USA), 300 mM of each primer (both MLL-AF9 and b2M) and 10 ng of cDNA. The PCR conditions were 1 cycle at 501C for 2 min, 1 cycle at 951C for 10 min and 50 cycles of 951C for 15, 601C for 1 min. Reactions were assayed on an ABI Prism 5700 Sequence Detection System (Applied Biosystems). The accumulation of PCR products was measured in real time as the increase in SYBRgreen fluorescence. Quantifications were carried out by the comparative DDCt method (Lafarge et al., 2001 ) and MLL-AF9 mRNA expression was normalized to the b2M housekeeping gene. The experiment was repeated three times with similar results
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ODNas only induces a moderate increase in apoptosis, suggesting that other contributory antiapoptotic factors (in addition to MLL-AF9) must exist in THP-1 cells. In other words, MLL-AF9 seems to be a proliferative factor that also exerts some antiapoptotic effects. This concept is in keeping with two other related observations: (1) MLL-AF9 expression causes an initial, nonmalignant expansion of myeloid precursors both in vivo and in vitro (Corral et al., 1996; Dobson et al., 1999; Johnson et al., 2003; Schulte et al., 2002) , while patients affected by MLL-AF9-related leukaemia show hyperleucocytosis and hypercellular marrow (Dimartino and Cleary, 1999) ; (2) although MLL-AF9 abrogates GADD34-induced apoptosis (Adler et al., 1999) , human monoblastic UG3 cells harbouring t(9;11) require exogenous growth factors such as CSFs or interleukin-3-(IL-3) for viability and proliferation (Ikeda et al., 1998b) , indicating that MLL-AF9 expression is not itself sufficient to abolish apoptosis.
No morphological evidence of monocyte-macrophage terminal differentiation was observable in MLL-AF9-PS-ODNas-treated THP-1 cells (Figure 2b) . Functionally, after 24-48 h, this treatment did not increase the THP-1 cells' capacity to reduce NBT or to phagocyte latex beads, and had no effect on the expression of CD11b, CD14 or CD61 monocytemacrophage differentiation markers (Table 1) . Conversely, the treatment of THP-1 cells with PMA (positive control) induced all these phenomena (Table 1) . Furthermore, in THP-1 cells (1 Â 10 5 cells/ml) pretreated for 24 h with MLL-AF9-PS-ODNas, terminal differentiation was never (in three separate experiments) inducible by adding either rh-(recombinant human)-M-CSF (100 ng/ml; Sigma), rhG-CSF-filgrastim (10 ng/ml; Roche) or rhGM-CSF-molgramostim (5 ng/ml; Novar- tis-Farma, Origgio, Italy). Even after 1 week, no morphologic modification or increase in cell adherence was observable, and cells treated with MLL-AF9-PSODNas plus either rhM-CSF, rhG-CSF or rhGM-CSF were indistinguishable from those treated with MLL-AF9-PS-ODNas alone (Figure 2b ). The finding that targeted MLL-AF9 downregulation does not induce terminal differentiation or restore CSF-induced differentiation suggests that mutations other than MLL-AF9 block CSF-induced terminal differentiation in THP-1 cells.
The overall phenotype of THP-1 cells was unaffected by MLL-AF9-PS-ODNas treatment after 24-48 h ( Table 1 ), suggesting that MLL-AF9 does not directly commit a haemopoietic progenitor to the monocyte lineage. Given the association of t(9;11) with AML-M5, the observation that MLL-AF9 neither blocks nor directly induces monocyte phenotype in THP-1 cells leads us to hypothesize that MLL-AF9 expression may indirectly favour monocyte differentiation by preserving the expression of other genes that directly induce monocyte commitment (Friedman, 2002) . This scenario is consistent with at least three other observations. First, in THP-1 cells MLL-AF9-targeted downregulation by MLL-AF9-PS-ODNas reduces the expression of HOXA7 and HOXA10; both these genes are leukaemogenic (Kawagoe et al., 2001; Owens and Hawley, 2002) , and the HOXA10 transcription factor induces monocytic-lineage commitment (Taghon et al., 2002) . Second, MLLwt (wild-type) is a positive regulator of HOX genes, affecting their maintenance rather than their developmental activation (Yu et al., 1995; Ayton and Cleary, 2001 ). Third, chimaeric MLL proteins share a similar nuclear localization to MLLwt (Joh et al., 1996 (Joh et al., , 1997 Butler et al., 1997) , suggesting that they could target the same genomic sites, thereby disrupting the expression of genes normally subordinate to MLL, including certain HOX genes.
We also examined MLL-AF9 expression during alltrans-retinoic-acid-(ATRA)-or phorbol-ester-(PMA/ Note: THP-1 cells were cultured with 20 mM MLL-AF9-PS-ODNas (as described in Figure 1 ) or the cells (2.5 Â 10 5 cell/ml) were cultured in normal growth medium supplemented with 20 mM PMA, used as positive control. Values are means7s.d. from three separate experiments (note that although CD4 and CD7 are ALL-T diagnostic markers, they are also expressed in the myeloid lineage). Adherence. Cells were considered to be adherent if they resisted vigorous shaking of the culture flask and washing by pipetting with normal growth medium. Phagocytosis and NBTreduction tests. For phagocytosis, 1 ml of a 2.5% suspension of fluorescinated-latex-beads (2 mm-diameter; Sigma) was added to control and treated cells (5 Â 10 5 cells/ml). For NBT-reduction, control and treated cells (5 Â 10 5 cells/ml) were resuspended in 200 ml PBS-(phosphatebuffered-saline) containing 0.1% NBT and 100 ng/ml PMA. In both tests, after incubation (371C for 60 min) the cells were stained with MayGrunwald-Giemsa and viewed using fluorescence microscopy (for phagocytosis; cells were also PBS-washed to remove excess beads) or light microscopy (for NBT). The percentage of cells with ingested latex-beads or containing blue black granules was examined by scoring at least 300 cells. CD analysis. The FITC-conjugated monoclonal antibodies CD3-(clone-SK7), CD4-(clone-SK3), CD5-(clone-L17F12), CD7-(clone-4H9), CD10-(clone-HI10a), CD11b-(clone-D12), CD14-(clone-M P P9), CD15-(clone-MMA), CD19-(clone-4G7), CD33-(clone-P67.6), CD41a-(clone-HIP8), CD42a-(clone-Bebl) and CD61-(clone-RUUPL7F12) were purchased from Becton-Dickinson. Control and treated cells (1 Â 10 6 cells/ml in PBS) were incubated with antibody at room temperature for 15 min, PBS-washed and analysed using FACSCALIBUR-flow-cytometer (Becton-Dickinson).
Functional role of the MLL-AF9 oncogene in THP-1 cells A Pession et al TPA)-induced terminal monocyte-macrophage differentiation of THP-1 cells (Matikainen and Hurme, 1994) . Real-time RT-PCR analysis revealed that MLL-AF9 expression was downregulated in both ATRA-and PMA-treated cells (Figure 3a,b) . Downregulation started earlier after PMA treatment (after 6 h of exposure vs 12-24 h with ATRA), supporting the concept that in THP-1 cells the PMA-induced signalling pathway is more rapid and effective than the ATRAinduced one (Matikainen and Hurme, 1994) . Taken together, the findings of the present study demonstrate that although MLL-AF9 downregulation occurs during monocytemacrophage terminal differentiation, this downregulation is not in itself sufficient to induce terminal differentiation in THP-1 cells. This concept fits with the multistep cellular differentiation process, in that although MLL-AF9 expression can favour the early monocytic lineage, further stimuli are then required for monocyte-macrophage terminal maturation. While modulating the expression of various genes, the latter stimuli also downregulate MLL-AF9 expression. In ATRA-and PMA-treated THP-1 cells, other genes are downregulated, including the MYC proto-oncogene (Matikainen and Hurme, 1994) , suggesting that both MYC and MLL-AF9 are present in malignant, but not in differentiated THP-1 cells.
Like MLL-AF9, the MLL-CBP fusion gene originating from t(11;16)(q23;p13) is also downregulated during terminal differentiation of SN-1 leukaemic cells carrying the t(11;16) (Niitsu et al., 2001) . Thus, two different MLL fusion genes are now known to be downregulated during terminal cellular differentiation. MLLwt downregulation occurs in normal haemopoietic differentiation (Kawagoe et al., 1999) , and MLL fusion genes are all under the control of the MLLwt promoter. This suggests that the expression of MLL-AF9 or MLLwt occurs only during early phases of monocytic development, prior to downregulation during terminal cellular maturation. Moreover, MLL expression in human peripheral blood mononuclear cells dramatically increases after treatment with mitogens (Ennas et al., 1997; Caslini et al., 2000) , again suggesting that MLLwt -and probably several MLL fusion genes -may play an important role in proliferation (a process absent in fully differentiated cells). Of note, MLL-CBP expression in SN-1 cells dominantly suppresses ATRAor VD3-(1a,25-dihydroxyvitamin-D 3 )-induced differentiation (Niitsu et al., 2001) . Conversely, in THP-1 cells MLL-AF9 expression does not block either ATRA-or VD3-induced differentiation (Schwende et al., 1996) , or -as reported here -CSF-induced differentiation. Finally, UG3 cells, which also express MLL-AF9, differentiate to macrophages after treatment with M-CSF or GM-CSF; to granulocytes with G-CSF; to osteoclast-like cells with M-CSF plus IL-4; and to multinucleated giant cells with M-CSF plus either IL-4 or IL-13 (Ikeda et al., 1998a, b) . Together, these observations indicate that MLL-AF9 expression is compatible with the normal developmental programmes of several myelomonocyte-lineage cells. By contrast, MLL-CBP expression blocks terminal differentiation. Therefore, different MLL fusion genes may have different effects on specific cellular maturation signalling pathways in relation to their respective translocation partners.
In summary, the results obtained in the THP-1 model lead us to hypothesize that MLL-AF9 oncogene expression deregulates target genes subordinated to MLLwt, including specific HOX-genes. By favouring hyperproliferation of certain haematopoietic progenitors (especially ones committed to the monocytic lineage), MLL-AF9 could maintain commitment to the myelomonocytic phenotype without blocking terminal differentiation. The appearance of further tumorigenic mutations would then be needed for neoplastic transformation. MLL-AF9 would then maintain its functions in the fully leukaemic cells (where it remains expressed). Thus, as well as directly promoting cell growth in both nonmalignant and malignant haematopoietic cells, MLL-AF9 may also indirectly determine phenotype. Ultimately, our data also imply that the search for other leukaemogenic mutations determining the development and aggressiveness of MLL-AF9-related leukaemias should focus on the processes of resistance to apoptosis (where MLL-AF9 seems to play only a limited role) and differentiation blockage (where MLL-AF9 may play no role at all). 
